Hepatitis B Virus (HBV) Market Report 2026
Global Outlook – By Type (Acute, Chronic), By Treatment (Immune Modulator Drugs, Antiviral Drugs, Vaccine, Surgery), By Age Group (Pediatrics, Adults, Seniors), By End User (Medical Providers, Patients, Healthcare Payers) – Market Size, Trends, Strategies, and Forecast to 2030
Hepatitis B Virus (HBV) Market Overview
• Hepatitis B Virus (HBV) market size has reached to $7.31 billion in 2025 • Expected to grow to $11.77 billion in 2030 at a compound annual growth rate (CAGR) of 10.2% • Growth Driver: Rising Hepatitis B Infection Rates Fuel Growth Prospects For Hepatitis B Virus Market • Market Trend: Advancement Of Next-Generation HBV Therapies Through Accelerated Clinical Trials And Regulatory Momentum • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Hepatitis B Virus (HBV) Market?
Hepatitis B virus (HBV) is a viral infection targeting the liver, transmitted via exposure to contaminated blood or bodily fluids or vertical transmission from mother to child during childbirth. Treatment involves antiviral medications to suppress viral replication, with vaccination being a crucial preventive measure. The main types of hepatitis B virus (HBV) are acute and chronic. Acute hepatitis B refers to a short-term infection caused by the hepatitis B virus that occurs within the first six months of exposure to the virus and the medications aim to clear the virus from the body and prevent chronic infection. They are treated with immune modulator drugs, antiviral drugs, vaccines, and surgery for different age groups, such as pediatrics, adults, and seniors, by medical providers, patients, and healthcare payers.
What Is The Hepatitis B Virus (HBV) Market Size and Share 2026?
The hepatitis b virus (hbv) market size has grown strongly in recent years. It will grow from $7.31 billion in 2025 to $7.98 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to high prevalence of hbv in asia-pacific, limited awareness about hbv treatment, low vaccination coverage in early years, reliance on generic antiviral drugs, rising incidence of chronic liver disease.What Is The Hepatitis B Virus (HBV) Market Growth Forecast?
The hepatitis b virus (hbv) market size is expected to see rapid growth in the next few years. It will grow to $11.77 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing r&d in hbv therapeutics, expansion of government vaccination programs, adoption of precision medicine, rising healthcare expenditure, growth in screening and diagnostic infrastructure. Major trends in the forecast period include increasing adoption of antiviral therapies, rising hepatitis b vaccination programs, development of combination therapies, focus on pediatric and geriatric hbv management, expansion of screening and diagnostic services.
Global Hepatitis B Virus (HBV) Market Segmentation
1) By Type: Acute, Chronic 2) By Treatment: Immune Modulator Drugs, Antiviral Drugs, Vaccine, Surgery 3) By Age Group: Pediatrics, Adults, Seniors 4) By End User: Medical Providers, Patients, Healthcare Payers Subsegments: 1) By Acute HBV: Asymptomatic Acute HBV, Symptomatic Acute HBV, Severe Acute HBV 2) By Chronic HBV: Chronic Hepatitis B (HBeAg Positive), Chronic Hepatitis B (HBeAg Negative), Chronic Hepatitis B With Compensated Liver Disease, Chronic Hepatitis B With Decompensated Liver Disease, Chronic Hepatitis B With Hepatocellular Carcinoma (HCC)What Is The Driver Of The Hepatitis B Virus (HBV) Market?
The high prevalence of hepatitis B infection is expected to propel the growth of the hepatitis B virus market going forward. Hepatitis B is a liver infection brought on by the hepatitis B virus (HBV), which is prevented through vaccination. Rising hepatitis B infection rates can increase demand for diagnostic tests and treatment options. For instance, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency focusing on the control and prevention of disease, injury, and disability estimated 13,300 new hepatitis B infections and 69,800 new hepatitis C infections in 2023. Therefore, the high prevalence of hepatitis B infection will drive the hepatitis B virus market.Key Players In The Global Hepatitis B Virus (HBV) Market
Major companies operating in the hepatitis b virus (hbv) market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sanofi SA, GlaxoSmithKline PLC, Gilead Sciences Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Apotex Corp., Lupin Pharmaceuticals Inc., Cadila Healthcare Ltd., Dynavax Technologies Corporation, Accord Healthcare Inc., Par Pharmaceutical Inc., Arbutus Biopharma Corporation, Antios Therapeutics Inc.
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Hepatitis B Virus (HBV) Market Trends and Insights
Major companies operating in the HBV market are focusing on advancing innovative therapies through clinical trials and accelerating regulatory progress to enhance treatment efficacy and gain competitive advantage. For instance, in August 2025, Aligos Therapeutics, a US-based therapeutics company, has begun dosing patients in its Phase II B-SUPREME trial evaluating ALG-000184, a first-in-class oral capsid assembly modulator for chronic hepatitis B. The randomized, double-blind study will enroll about 200 treatment-naïve adults, comparing ALG-000184 to tenofovir disoproxil fumarate over 48 weeks. The primary goal is to achieve HBV DNA levels below quantifiable limits in both HBeAg-positive and HBeAg-negative participants, with secondary measures assessing safety, pharmacokinetics, and antigen changes. Earlier Phase I data showed strong antiviral activity and good tolerability, supporting the drug’s potential. Interim results are expected in 2026, with full topline findings anticipated in 2027.What Are Latest Mergers And Acquisitions In The Hepatitis B Virus (HBV) Market?
In July 2023, Brii Biosciences Ltd., a China-based biotechnology company, acquired licensing rights for an experimental hepatitis B immunotherapy and an approved hepatitis B vaccine from VBI Vaccines Inc. for an undisclosed amount. With this acquisition, Brii Biosciences Ltd. will have access to information on the prevention and treatment of the disease. VBI Vaccines Inc. is a US-based biotechnology company engaged in developing a vaccine to prevent infection caused by the hepatitis B virus.
Regional Insights
North America was the largest region in the hepatitis B Virus (HBV) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Hepatitis B Virus (HBV) Market?
The hepatitis B virus (HBV) market consists of revenues earned by entities by providing diagnostic testing for infection and monitoring of liver function. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis B virus (HBV) market also includes sales of tenofovir disoproxil, entecavir, telbivudine and lamivudine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Hepatitis B Virus (HBV) Market Report 2026?
The hepatitis b virus (hbv) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis b virus (hbv) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Hepatitis B Virus (HBV) Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $7.98 billion |
| Revenue Forecast In 2030 | $11.77 billion |
| Growth Rate | CAGR of 9.3% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Type, Treatment, Age Group, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sanofi SA, GlaxoSmithKline PLC, Gilead Sciences Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Apotex Corp., Lupin Pharmaceuticals Inc., Cadila Healthcare Ltd., Dynavax Technologies Corporation, Accord Healthcare Inc., Par Pharmaceutical Inc., Arbutus Biopharma Corporation, Antios Therapeutics Inc. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |